



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/509,591	06/02/2000	ANDREW S. LITTLE	CELL-006CIP	3648
75	7590 02/16/2005 EXAMI		NER	
Bozicevic, Field & Francis LLP			BURKHART, MICHAEL D	
1900 Univeristy Suite 200	Ave		ART UNIT	PAPER NUMBER
East Palo Alto, CA 94303			1636	
			DATE MAIL ED: 02/16/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		09/509,591		LITTLE ET AL.			
		Examiner	Art Unit	Τ			
		Michael D. Burkhart	1636				
	The MAILING DATE of this communication ap			ddress			
Period for Reply							
THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.7 SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a rep openiod for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailined patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, many within the statutory minimum of will apply and will expire SIX (6) a, cause the application to become	ay a reply be timely filed  of thirty (30) days will be considered time MONTHS from the mailing date of this ne ABANDONED (35 U.S.C. § 133).				
Status							
1)🖂	Responsive to communication(s) filed on 09 A	ugust 2002.					
2a)⊠	This action is <b>FINAL</b> . 2b) This	s action is non-final.					
3)	Since this application is in condition for allowa	nce except for formal r	natters, prosecution as to th	ne merits is			
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
4)⊠	4)⊠ Claim(s) <u>71-72, 76-84, 88-93, 98-101</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)[	5) Claim(s) is/are allowed.						
6)⊠	)⊠ Claim(s) <u>71,72,82-84 and 98-101</u> is/are rejected. )⊠ Claim(s) <u>76-81, 88-93</u> is/are objected to.						
7)🛛							
8)□	Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers						
9)[	The specification is objected to by the Examine	er.					
10)⊠ The drawing(s) filed on <u>1/07/03</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)⊠	The oath or declaration is objected to by the E	xaminer. Note the attac	ched Office Action or form P	'TO-152.			
Priority (	under 35 U.S.C. § 119						
	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:						
	<ol> <li>Certified copies of the priority document</li> <li>Certified copies of the priority document</li> </ol>						
	3. Copies of the certified copies of the prior		··· ——	al Stage			
	application from the International Burea	•		ii Otago			
* 5	See the attached detailed Office action for a list		not received.				
Attachmen	at(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 5) Notice of Informal Patent Application (PTO-1449 or PTO/SB/08)							
Paper No(s)/Mail Date 6) Other:							

## **DETAILED ACTION**

## Oath/Declaration

The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because: The filing date for the 09/509,591 application is erroneously listed as 9/3/99 rather than the correct date of 6/2/2000.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 71, 72, 82-84, and 98-101 are rejected under 35 U.S.C. 102(e) as being anticipated by Hallenbeck et al (cited by applicants). This rejection is maintained for reasons of record in the previous Office Action and for reasons outlined below. Applicants traverse this

Art Unit: 1636

rejection by asserting that Hallenbeck et al teaches only a method of expressing a heterologous gene product and that the concept of selective cytolysis, as found in the instant claims, is neither recited nor described. Applicants also argue that Hallenbeck et al. do not teach the claimed adenoviral vectors with more than one essential gene under control of a tissue-specific TRE.

Applicants' arguments filed 8/9/2002 have been fully considered but they are not persuasive. The adenovirus described by Hallenbeck would be cytotoxic upon expression of the E1a, E1b or E4 genes that are essential for replication. Such expression would occur only when the AFP-TRE is activated, i.e. in the liver or hepatocytes, and is thus selective. Hallenbeck et al also teach multiple adenovirus genes essential for replication under control of a TRE. See column 9, lines 48-50; "For example, a single transcriptional regulatory sequence could be used to drive replication by more than one gene essential for replication.", and lines 52-55; "An example is a heterologous promoter linked to a cassette containing E1a coding sequences (E1 promoter deleted) and the entire E1b gene." Also see column 10, lines 6-8; "In one embodiment, both E1a and E1b are operably linked to heterologous tissue-specific transcriptional regulatory sequences." Hallenbeck et al also disclose that other genes essential for replication, such as E2-E4, may also be used, see column 10, lines 17-20.

Applicants' have amended claim 83 to read on a method that comprises a vector with more than one adenovirus gene essential for replication under control of an AFP-TRE. As such, claim 83 falls within the scope of Hallenbeck et al. Applicants also claim methods comprising vectors that comprise a silencer or encode GM-CSF. Hallenbeck et al teach the use of other genetic control elements, such as silencers (column 6, lines 15-17) and that the vector may encode a cytokine, such as GM-CSF (column 14, lines 65-67).

Claims 76-81 and 88-93 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any rejections not repeated in this office action are withdrawn.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael D. Burkhart whose telephone number is (571) 272-2915. The examiner can normally be reached on M-F 8AM-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/509,591

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

Michael D. Burkhart

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit 1636

Examiner

PRIMARY EXAMINER

Page 5